Adaptor Protein Lnk Binds to and Inhibits Normal and Leukemic FLT3

被引：0

作者：

Lin, Dechen ^{[1
]}

Yin, Tong ^{[1
]}

Koren-Michowitz, Maya ^{[1
]}

Ding, Ling-Wen ^{[2
]}

Gueller, Saskia ^{[3
]}

Gery, Sigal ^{[1
]}

Tabayashi, Takayuki ^{[1
]}

Bergholz, Ulla ^{[4
]}

Kazi, Julhash ^{[5
]}

Ronnstrand, Lars ^{[5
]}

Stocking, Carol ^{[4
]}

Koeffler, Phillip ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA

[2] Canc Sci Inst Singapore, Singapore, Singapore

[3] Goethe Univ Frankfurt, Dept Med, D-60054 Frankfurt, Germany

[4] Heinrich Pette Inst, Hamburg, Germany

[5] Lund Univ, Skane Univ Hosp, Malmo, Sweden

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.1312.1312

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1312

引用

页数：2

共 50 条

[31] Statin Treatment Inhibits FLT3 Signaling by Preventing Glycosylation of the Mature Receptor and Leads to Cell Death In Mutant FLT3 Expressing Cells
Williams, Allen
Bao Nguyen
Li, Li
Brown, Patrick
Levis, Mark J.
Small, Donald
BLOOD, 2010, 116 (21) : 342 - 342
[32] Evaluation of a FLT3 inhibitor as an anti-leukemic agent for acute myeloid leukemia
Jeong, Pyeonghwa
Lee, Jungeun
Lee, Hyo Jeong
Baek, Juhwa
Choi, Jungil
Chin, Young-Won
Choi, Young Hee
Kim, Yong-Chul
Han, Sun-Young
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
[33] DNA damage synergizes with FLT3 inhibition to induce apoptosis in leukemic cells.
Ahn, JY
Small, D
BLOOD, 2003, 102 (11) : 204B - 204B
[34] Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction
Tickenbrock, L
Schwäble, J
Wiedehage, M
Steffen, B
Sargin, B
Choudhary, C
Brandts, C
Berdel, WE
Müller-Tidow, C
Serve, H
BLOOD, 2005, 105 (09) : 3699 - 3706
[35] Ligand-independent autophosphorylation of Flt3 in leukemic blasts of patients with ANLL.
Serve, H
Flesch, K
Fenski, R
Serve, S
Schwartz, S
Gunther, J
Neuloh, M
Thiel, E
Berdel, WE
BLOOD, 1997, 90 (10) : 3612 - 3612
[36] Adaptor protein Lnk binds to PDGFRA, PDGFRB and FIP1L1-PDGFRA, but not to the TEL-PDGFRB fusion protein.
Gueller, Saskia
Gery, Sigal
Koeffler, H. Phillip
BLOOD, 2007, 110 (11) : 657A - 657A
[37] The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
Spiekermann, K
Dirschinger, RJ
Schwab, R
Bagrintseva, K
Faber, F
Buske, C
Schnittger, S
Kelly, LM
Gilliland, DG
Hiddemann, W
BLOOD, 2003, 101 (04) : 1494 - 1504
[38] FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations - FLT3 in AML: Much more to learn about biology and optimal targeting
Giles, Francis J.
LEUKEMIA RESEARCH, 2006, 30 (12) : 1469 - 1470
[39] A FLT3 gene-expression signature outperforms FLT3 status in predicting clinical outcome for patients with normal karyotype AML.
Bullinger, Lars
Dohner, Konstanze
Stimer, Christoph
Rucker, Frank G.
Frohling, Stefan
Kim, Young H.
Schlenk, Richard F.
Tibshirani, Robert
Dohner, Hartmut
Pollack, Jonathan R.
BLOOD, 2006, 108 (11) : 655A - 655A
[40] TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax
Tyagi, Anudishi
Jaggupilli, Appalaraju
Ly, Stanley
Yuan, Bin
El-Dana, Fouad
Hegde, Venkatesh L.
Anand, Vivek
Kumar, Bijender
Puppala, Mamta
Yin, Zheng
Wong, Stephen T. C.
Mollard, Alexis
Vankayalapati, Hariprasad
Foulks, Jason M.
Warner, Steven L.
Daver, Naval
Borthakur, Gautam
Battula, V. Lokesh
LEUKEMIA, 2024, 38 (01) : 82 - 95

← 1 2 3 4 5 →